Crosstalk between interferon and interleukin-1 antiviral signaling in cancer cells: implications for immune evasion and therapeutic resistance

Morten Frier Gjerstorff

doi:10.3389/fimmu.2023.1219870

Crosstalk between interferon and interleukin-1 antiviral signaling in cancer cells: implications for immune evasion and therapeutic resistance

Front Immunol. 2023 Jun 8:14:1219870. doi: 10.3389/fimmu.2023.1219870. eCollection 2023.

Author

Morten Frier Gjerstorff^{1

2

3}

Affiliations

¹ Department of Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, ;Denmark.
² Department of Oncology, Odense University Hospital, Odense, Denmark.
³ Academy of Geriatric Cancer Research (AgeCare), Odense University Hospital, Odense, Denmark.

No abstract available

Keywords: interferon; interleukin 1; myeloid-derived suppressor cells (MDSC); therapeutic resistance; tumor immunity.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antiviral Agents* / pharmacology
Antiviral Agents* / therapeutic use
Drug Resistance, Neoplasm
Immune Evasion
Interferons
Interleukin-1
Neoplasms* / drug therapy

Substances

Antiviral Agents
Interferons
Interleukin-1

Grants and funding

The study was supported by the Region of Southern Denmark, Pink Tribute, Einar Willumsens foundation, Carl and Ellen Hertzs foundation, Phycician Sofus Carl Emil Friis and spouse’s foundation, Neye foundation, Agnes and Poul Friis foundation, Emil C. Hertz and spouse’s foundation, Frimodt-Heineke foundation, Olga Doris Friis foundation, Dagmar Marshalls foundation, the Danish Cancer Society, the Novo Nordisk foundation, and the Danish Research Council for Independent Research. The funders were not involved in the study design, collection, analysis,interpretation of data, the writing of this article or the decision to submit it for publication.